Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia

Oncogene

Volumn 26, Issue 5, 2007, Pages 765-773

  Wu, Y ^a   McRoberts, K ^a   Berr, S S ^b   Frierson Jr , H F ^a   Conaway, M ^b   Theodorescu, D ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bladder neoplasms; Endothelial growth factors; Gene expression profiling; Neoplasm metastasis; Xenograft model antitumor assays

Indexed keywords

NEUROMEDIN U; PROTEIN; RHO GUANOSINE DIPHOSPHATE DISSOCIATION INHIBITOR 2 PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BLADDER CANCER; BODY WEIGHT; CACHEXIA; CANCER GROWTH; CELL LINE; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE OVEREXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CARCINOGENESIS; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; RNA INTERFERENCE; RNA SYNTHESIS; WEIGHT REDUCTION; XENOGRAFT;

ANIMALS; CACHEXIA; CARCINOMA, TRANSITIONAL CELL; CELL ADHESION; CELL PROLIFERATION; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEUROPEPTIDES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

ANIMALIA; MUS MUSCULUS;

EID: 33846846542     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209835     Document Type: Article

References (42)

1. Alevizos I, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Posner M et al. (2001). Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 20: 6196-6204.
2. Brighton PJ, Szekeres PG, Willars GB. (2004). Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol Rev 56: 231-248.
3. Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC et al. (2000). Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 60: 2541-2546.
4. Cao CQ, Yu XH, Dray A, Filosa A, Perkins MN. (2003). A pro-nociceptive role of neuromedin U in adult mice. Pain 104: 609-616.
5. Chan IS, Zhang Z. (1999). Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 55: 1202-1209.
6. Chung LW, Baseman A, Assikis V, Zhau HE. (2005). Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10-20.
7. Clark EA, Golub TR, Lander ES, Hynes RO. (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535.
8. Euer NI, Kaul S, Deissler H, Mobus VJ, Zeillinger R, Weidle UH. (2005). Identification of L1CAM, Jagged2 and neuromedin U as ovarian cancer-associated antigens. Oncol Rep 13: 375-387.
9. Fidler IJ, Ellis LM. (1994). The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188.
10. Gildea JJ, Golden WL, Harding MA, Theodorescu D. (2000). Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 27: 252-263.
11. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA et al. (2002). RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 62: 6418-6423.
12. Hanada R, Teranishi H, Pearson JT, Kurokawa M, Hosoda H, Fukushima N et al. (2004). Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat Med 10: 1067-1073.
13. Harding MA, Arden KC, Gildea JW, Gildea JJ, Perlman EJ, Viars C et al. (2002). Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res 62: 6981-6989.
14. Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM et al. (2000). Identification of receptors for neuromedin U and its role in feeding. Nature 406: 70-74.
15. Ida T, Mori K, Miyazato M, Egi Y, Abe S, Nakahara K et al. (2005). Neuromedin S is a novel anorexigenic hormone. Endocrinology 146: 4217-4223.
16. Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA et al. (2004). Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64: 8613-8619.
17. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. (2003). Cancer statistics, 2003. CA Cancer J Clin 53: 5-26.
18. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. (2003). In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metast 20: 745-756.
19. Johnson EN, Appelbaum ER, Carpenter DC, Cox RF, Disa J, Foley JJ et al. (2004). Neuromedin U elicits cytokine release in murine Th2-type T cell clone D10.G4.1. J Immunol 173: 7230-7238.
20. Kamai T, Kawakami S, Koga F, Arai G, Takagi K, Arai K et al. (2003a). RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer. BJU Int 91: 234-238.
21. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y et al. (2003b). Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9: 2632-2641.
22. Kowalski TJ, Spar BD, Markowitz L, Maguire M, Golovko A, Yang S et al. (2005). Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice. J Endocrinol 185: 151-164.
23. Martignoni ME, Kunze P, Friess H. (2003). Cancer cachexia. Mol Cancer 2: 36.
24. Moriyama M, Matsukawa A, Kudoh S, Takahashi T, Sato T, Kano T et al. (2006). The neuropeptide neuromedin U promotes IL-6 production from macrophages and endotoxin shock. Biochem Biophys Res Commun 341: 1149-1154.
25. Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kangawa K et al. (2005). The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med 202: 217-224.
26. Nelson J, Bagnato A, Battistini B, Nisen P. (2003). The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116.
27. Oxford G, Theodorescu D. (2003). The role of Ras superfamily proteins in bladder cancer progression. J Urol 170: 1987-1993.
28. Robinson VL, Kauffman EC, Sokoloff MH, Rinker-Schaeffer CW. (2004). The basic biology of metastasis. Cancer Treat Res 118: 1-21.
29. Sahai E, Marshall CJ. (2002). RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142.
30. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. (2000). The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metast 18: 519-525.
31. Shetzline SE, Rallapalli R, Dowd KJ, Zou S, Nakata Y, Swider CR et al. (2004). Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood 104: 1833-1840.
32. Shousha S, Nakahara K, Sato M, Mori K, Miyazato M, Kangawa K et al. (2006). Effect of neuromedin S on feeding regulation in the Japanese quail. Neurosci Lett 391: 87-90.
33. Steeg PS. (2003). Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3: 55-63.
34. Strassmann G, Kambayashi T. (1995). Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. Cytokines Mol Ther 1: 107-113.
35. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson Jr HF. (2004). Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10: 3800-3806.
36. Tisdale MJ. (2005). Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 20: 340-348.
37. Titus B, Frierson Jr HF, Conaway M, Ching K, Guise T, Chirgwin J et al. (2005). Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 65: 7320-7327.
38. Welch DR. (2004). Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res 6: 61-64.
39. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M et al. (2002). Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485-495.
40. Yu XH, Cao CQ, Mennicken F, Puma C, Dray A, O'Donnell D et al. (2003). Pro-nociceptive effects of neuromedin U in rat. Neuroscience 120: 467-474.
41. Zheng X, Hu Y, Liu J, Ouyang K. (2005). Screening of active compounds as neuromedin U2 receptor agonist from natural products. Bioorg Med Chem Lett 15: 4531-4535.
42. Zhou X, Suto S, Ota T, Tatsuka M. (2004). Nuclear translocation of cleaved LyGDI dissociated from Rho and Rac during Trp53-dependent ionizing radiation-induced apoptosis of thymus cells in vitro. Radiat Res 162: 287-295.